How common is 17p deletion in CLL?
Chromosome 17p deletion is seen in 5-9% of patients with newly diagnosed CLL; however, it represents the most common genetic aberration (≈50%) in patients with refractory/relapsed CLL.
Is CLL with 17p deletion rare?
Although the 17p deletion [del(17p)] is rare in cases of treatment-naive chronic lymphocytic leukemia (CLL), its frequency is higher in refractory/relapsed CLL – particularly in patients undergoing chemo(immuno)therapy.
What causes 17p deletion?
A deletion of 17p commonly involves the tumor suppressor gene p53 on band 17p13. 1 with allelic loss of the gene. p53 is a tumor suppressor that induces cell-cycle arrest with following DNA repair or apoptotic cell death in response to genotoxic substances, oncogenes, hypoxia, DNA damage or ribonucleotide depletion.
How common is TP53 mutation in CLL?
TP53 mutations Somatic mutations in TP53 are observed in CLL in ~10% of cases at diagnosis and are often associated with del(17p). Indeed, almost 80% of cases with del(17p) will harbor a TP53 mutation in the remaining allele, a phenomenon referred to as loss of heterozygosity (LOH).
Does 17p deletion go away?
It is also known that not all patients with CLL and deletion 17p have poor clinical outcomes. There are instances of patients with deletion 17p surviving for more than 10 years without any treatment.
What does 17p deletion mean?
Deletion 17p (del 17p) is a rare genomic aberration found in patients with chronic lymphocytic leukemia (CLL).
How do you test for IGHV mutation?
Currently, IGHV mutational status is determined by amplifying the IGHV transcript by polymerase chain reaction (PCR), sequencing the gene through Sanger sequencing, and comparing the transcript to known germline genes available in immunoglobulin databases.
How do you test for 17p deletion?
Fluorescent in situ hybridization (FISH) is a molecular cytogenetic technique used to test the presence or absence of specific chromosome regions and is often used to detect chromosome deletions such as deletion 17p. This involves using a specific DNA probe which recognises the region to be tested.
What is 17p deletion in CLL?
In chronic lymphocytic leukemia (CLL), deletion (del) of the short arm of chromosome 17 (17p13) is found in 5 to 8% of patients requiring first-line treatment and is associated with rapid disease progression as well as a poor response to treatment with a median overall survival (OS) of 2 to 3 years from the time of …
Which of the following deletion is associated with poor prognosis in CLL SLL patients?
~Del (17p) which results in the loss of TP53, is the most important prognostic marker in CLL and is associated with poor outcomes, rapid disease progression and is historically associated with resistance to standard fludarabine-based chemoimmunotherapy….Prognostic Factors in CLL.
| Variable | Adverse Factor | Grading |
|---|---|---|
| Age | >65 years | 1 |
Should IGHV status and fish testing be performed in all CLL patients at diagnosis?
The cumulative evidence presented in this systematic review is sufficient to recommend that FISH and IGHV be performed as standard clinical tests for all patients with newly diagnosed CLL in those countries with the resources to do so.
What does Del 17p mean?
According to Dr. Orlowski: What the deletion of 17p means is that a portion of chromosome 17 on the short arm (which is what the p stands for) is actually deleted. When mapping has been done to try to identify what genes are mutated as a result, the gene that is most commonly found to be lost is the gene called p53.
Is 17p deletion/p53 mutation a risk factor for chronic lymphocytic leukemia (CLL)?
Refractory/early relapsed and 17p deletion/p53 mutation (del(17p)/TP53mut)-positive chronic lymphocytic leukemia (CLL) has been conventionally considered a high-risk disease, potentially eligible for treatment with allogeneic stem cell transplantation (alloSCT).
How is chronic lymphocytic leukemia (CLL) with 17p deletion treated?
Conventional chemo-immunotherapy with rituximab in combinatio … Chronic lymphocytic leukemia (CLL) with 17p deletion or mutations of the TP53 gene has a very poor outcome. Optimal treatment of these patients remains a major clinical challenge, and disagreement on the optimal treatment approach exists.
What is the prognosis of deletion 17p (del 17p)?
The most important prognostic factor is the loss of parts of the short arm of chromosome 17, known as deletion 17p (del(17p)). A recent publication (on a small number of patients) suggested that these patients are at very high-risk only if del(17p) is associated with TP53 mutations, the so-called “double-hit” population.
Is TP53 disruption a prognostic factor in chronic lymphocytic leukemia?
TP53 disruption is considered to be the most important prognostic factor in chronic lymphocytic leukemia (CLL), but not all patients with TP53 disruption have similar dismal outcomes. We evaluated the prognostic value of TP53 disruption in CLL patients without treatment indications.